Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...

Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...

New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial ...

GLP-1 drugs like Ozempic and Wegovy are transforming public health and consumer habits. Here we explore their explosive ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...

Medically, you don’t have to taper off semaglutide, but many experts recommend it when stopping the medication. Some ...

GLP-1 initiation was common among patients who underwent bariatric surgery, especially sleeve gastrectomy vs Roux-en-Y gastric bypass.

Chemistry researchers at the University of Utah have uncovered an enzyme, dubbed PapB, that can "tie off" therapeutic ...

Henry Meds is a subscription-based telehealth platform that focuses on treatment for endocrine-related conditions. Offerings ...